How do MK-677 and sermorelin differ?

MK-677 acts at the ghrelin receptor and has been studied orally. Sermorelin is a peptide GHRH analog historically studied and marketed as an injected product.

Did MK-677 improve muscle function in older adults?

A randomized study found increased fat-free mass but no significant strength or function improvement. Its size and duration were insufficient to rule out a functional effect.

Are these currently FDA-approved products?

Ibutamoren has no FDA-approved product. The historical Geref sermorelin product was withdrawn from the market; its former approval does not establish a currently marketed approved anti-aging treatment.

Is combining them proven beneficial?

No controlled human combination trial cited here establishes clinical benefit or safety.

MK-677 vs Sermorelin: Evidence and Status

Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.

What the comparison can establish

MK-677 (ibutamoren) is a nonpeptide, orally studied growth hormone secretagogue acting at the ghrelin receptor. Sermorelin is a peptide growth hormone-releasing hormone (GHRH) analog. Receptor differences explain the research question; they do not establish that one has better muscle, sleep, metabolic or longevity outcomes. FDA ibutamoren evaluation; FDA review noting Geref withdrawal.

Issue	MK-677	Sermorelin
Pathway	Ghrelin receptor	GHRH receptor
Studied formulation	Oral	Injected historical Geref product
FDA history	No approved ibutamoren product	Historical Geref approval, followed by market withdrawal
Anti-aging or strength benefit	Not established	Not established by the historical approval

In a randomized 65-person healthy older-adult MK-677 study, GH, IGF-1 and fat-free mass rose. Strength and function did not improve significantly, but the authors said the study was insufficiently powered and too short to evaluate functional endpoints. Visceral fat did not significantly decline. Fasting glucose rose and insulin sensitivity fell. The findings cannot be read as either proven functional benefit or proof that no functional effect is possible. Nass et al., PMID 18981485.

The FDA’s Geref record describes sermorelin’s historical approval and withdrawal and says the withdrawal was not for safety or effectiveness reasons. That determination does not establish a “cleaner” glucose profile than MK-677 or validate adult anti-aging use. We found no direct comparative metabolic or functional trial to rank the two. FDA medical review.

Merck ended its earlier MK-0677 program, but the same molecule is in later pediatric development as LUM-201. The official NCT06948214 Phase 3 registration was recruiting in the September 29, 2026 registry archive; neither a development program nor a compounding discussion makes ibutamoren FDA approved. FDA ibutamoren evaluation.

No cited controlled trial validates combining MK-677 with sermorelin. This page does not provide a treatment or sourcing recommendation.

MK-677 vs Sermorelin

MK-677

Sermorelin

What the comparison can establish

View Full Dossiers

Stay Updated on Peptide Comparisons